NexGard Spectra 9.375 mg + 1.875 mg - Chewable tablet

Authorised

- Afoxolaner
- Milbemycin oxime

Product identification

Medicine name:
NexGard Spectra 9.375 mg + 1.875 mg - Chewable tablet

Active substance:
Afoxolaner

Milbemycin oxime

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Afoxolaner

Presentation_strength:9.375 mg Reference:In house Index:0
Milbemycin oxime

Presentation_strength:1.875 mg Reference:In house Index:1

Pharmaceutical form:

Chewable tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QP54AB51

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Available in:

Belgium , Czechia , Estonia , France , Latvia , Lithuania , Luxembourg , Poland , Slovakia , Spain

Package description:

Packaging:Blister (PVC/Alu), Package_size:15 tablets

Packaging:Blister (PVC/Alu), Package_size:3 tablets

Packaging:Blister (PVC/Alu), Package_size:6 tablets (1 blister of 6 tablets)

Packaging:Blister (PVC/Alu), Package_size:1 tablet

Packaging:Blister (PVC/Alu), Package_size:6 tablets (2 blisters of 3 tablets)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Boehringer Ingelheim Vetmedica GmbH

Marketing authorisation date:
15/01/2015

Manufacturing sites for batch release:
Boehringer Ingelheim Animal Health France

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
15/12/2022

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 6/02/2026
Download

ema-puar-v3842-nexgardspectra-ws-vra0000245082-en.pdf

ema-puar-v3842-nexgard-spectra-ws2280-g-vra-0034-g-en.pdf

ema-puar-nexgard-spectra-v-3842-var-ii-0008-en.pdf

ema-puar-nexgard-spectra-v-3842-var-ii-0019-en.pdf

ema-puar-nexgard-spectra-v-3842-par-en.pdf

ema-puar-nexgard-spectra-nex-spe-var-ws1559-en.pdf

ema-puar-nexgard-spectra-nex-spe-var-ws1338-en.pdf